On April 30th, SonoScape received the CE-marking, the product's "Passport to 
Europe", for its linear-array echoendoscope EG-UC5T. This further expands 
SonoScape's endoscopic ultrasound (EUS) portfolio in the international market. 
Reaping the benefits of decades of ultrasound technology know-how, SonoScape's 
EUS product line officially debuted in September 2019, when its 360° 
radial-array echoendoscope EG-UR5 obtained the CE Marking, leaping to the 4th 
company in the world to master the core technology of EUS. 

EG-UC5T is characterised by its large, 4.0-mm instrument channel and its short 
rigid distal end, pushing the boundaries of therapeutic excellence. With the 
arrival of the linear-array echoendoscope EG-UC5T, SonoScape users are not only 
able to perform the adequate tissue sampling, but also various therapeutic 
interventional endoscopic procedures under the sonographic guidance. This is a 
true "best of the two worlds", a golden key to reveal what's behind the GI 
tract mucosa and to unlock the growing possibilities of advanced endoscopy.

"SonoScape's EUS portfolio will certainly extend the company's path into more 
and larger hospitals. This again underpins the company's leading role in the 
global digestive endoscopy market." said Steven He, Sales Director of Endoscopy 
Division at SonoScape: "We have achieved great results with our current 
gastrointestinal endoscopes, and I am confident that the new linear-array 
echoendoscopes will set us to a higher success."

The last 25 years have witnessed a major expansion of EUS to various 
applications, both diagnostic and therapeutic, as noted in Friedberg SR, 
Lachter J, World Journal of Gastrointestinal Endoscopy (2017).  Focused on 
delivering high quality products, SonoScape continues to bring significant 
value to the world of endoscopy.

About SonoScape

Founded in 2002 in Shenzhen, China, SonoScape has committed itself to "Caring 
for life through innovation" by providing ultrasound and endoscopy solutions 
and delivering first-rate services. It now has seven R&D centers in Shenzhen, 
Shanghai, Harbin, Wuhan, Tokyo, Silicon Valley and Seattle. SonoScape invests 
nearly 20% of its revenues into R&D in recent 3 years, with more advanced 
products to be introduced into the pipeline.

SOURCE:  SonoScape Medical Corporation

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=395273

   Caption: CE Marking